Analysts at B. Riley started coverage on shares of AMAG Pharmaceuticals (NASDAQ:AMAG) in a research note issued to investors on Thursday. The firm set a “neutral” rating and a $16.00 price target on the specialty pharmaceutical company’s stock. B. Riley’s target price indicates a potential upside of 14.70% from the company’s current price.
Other analysts have also issued reports about the company. Piper Jaffray Companies began coverage on AMAG Pharmaceuticals in a research report on Monday, October 23rd. They issued a “neutral” rating and a $18.00 target price for the company. BidaskClub lowered AMAG Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Thursday, August 10th. Cowen reissued a “hold” rating on shares of AMAG Pharmaceuticals in a report on Thursday, August 10th. Zacks Investment Research raised AMAG Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Wednesday, November 8th. Finally, Janney Montgomery Scott reissued a “hold” rating on shares of AMAG Pharmaceuticals in a report on Tuesday, October 17th. Two investment analysts have rated the stock with a sell rating, thirteen have given a hold rating and three have assigned a buy rating to the company. The stock has an average rating of “Hold” and an average target price of $23.38.
Shares of AMAG Pharmaceuticals (NASDAQ AMAG) opened at $13.95 on Thursday. AMAG Pharmaceuticals has a 12-month low of $11.93 and a 12-month high of $36.83. The company has a debt-to-equity ratio of 0.94, a current ratio of 1.59 and a quick ratio of 1.48.
COPYRIGHT VIOLATION WARNING: This article was originally reported by Sports Perspectives and is the sole property of of Sports Perspectives. If you are reading this article on another site, it was illegally stolen and reposted in violation of US and international copyright law. The original version of this article can be read at https://sportsperspectives.com/2017/12/07/amag-pharmaceuticals-amag-earns-neutral-rating-from-analysts-at-b-riley.html.
About AMAG Pharmaceuticals
AMAG Pharmaceuticals, Inc is a pharmaceutical company. The Company’s segment is the manufacture, development and commercialization of products and services for use in treating various conditions, with a focus on maternal health, anemia management and cancer supportive care. Its offerings focus on maternal health, anemia management and cancer supportive care, including its product, Makena (hydroxyprogesterone caproate injection); services related to the collection, processing and storage of umbilical cord blood stem cell and cord tissue units operated through Cord Blood Registry (CBR); its product, Feraheme (ferumoxytol), for intravenous (IV) use, and MuGard Mucoadhesive Oral Wound Rinse.
Receive News & Ratings for AMAG Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AMAG Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.